An observational study in Hepatocellular Carcinoma, Cholangiocarcinoma and Metastatic Colon Cancer, sponsored by IRCCS San Raffaele. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-12.
Sponsored by IRCCS San Raffaele · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 206 studies in Carcinoma, Hepatocellular with a site in Italy — 49 open to participants now, 74 under way, 12 of them phase 3. Carcinoma, Hepatocellular · Italy.
Among the 206 studies in Carcinoma, Hepatocellular with a site in Italy, this one is the 17th largest by planned enrollment of the 60 observational ones that give a count, is one of 17 that started in 2021, is one of 61 observational ones, reaches primary completion later than 36 of the 73 other live ones, and was the 153rd registered.
3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.
Browse Carcinoma, Hepatocellular studies →49 of the 206 studies in Carcinoma, Hepatocellular with a site in Italy are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Italy
Ages 18–100
IRCCS Azienda Ospedaliero-Universitaria di Bologna · Sites in Italy
Ages 18–64
CatalYm GmbH · Sites in Italy, United States, France and 4 more countries
Ages 18–100
Bristol-Myers Squibb · Sites in Italy, United States, Australia and 11 more countries
Ages 18+
Niguarda Hospital · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
206 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 52 · Phase 3 49 · Phase 4 3
First in 1998; this study’s year is marked. 17 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 580 is above the median of 200 across 853 observational studies indexed under Carcinoma, Hepatocellular.
Median enrollment 156 across the 144 interventional studies, 200 across the 60 observational. Of the 116 that completed or were terminated, 48 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
115 of 206 have an industry lead sponsor. The 10 most frequent:
IRCCS San Raffaele is the lead sponsor of 458 studies on the registry; 237 are open to participants now.
IRCCS San Raffaele has 2 studies filed under Carcinoma, Hepatocellular — fewer than ten, so there is no comparison to draw.
15 of the studies in Carcinoma, Hepatocellular with a site in Italy that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04523493Phase 3Shanghai Junshi Bioscience Co., Ltd.Phase III Study of Toripalimab(JS001) Combined With Lenvatinib for Advanced HCC | 2026-12-31 |
| NCT06109272Phase 3AbbVieA Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) | 2027-01 |
| NCT04803994Phase 3Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestThe ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma | 2027-07 |
| NCT05822752AbbVieStudy to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) | 2026-11 |
| NCT05911633Terumo Europe N.V.BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC) | 2026-11-30 |
Add all 15 to your calendar (.ics) → With an account.
Among the 206 studies in Carcinoma, Hepatocellular with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this evaluate short, medium and long term outcome of the different embolization techniques in patients with primary and secondary hepatic tumors. The main aim is to evaluate progression free survival following embolization in this study population or evaluate residual hepatic volume in cases in which these techniques are used to induce liver regeneration. This study is an observational registry - all patients will follow their normal therapeutic and treatment scheme as per clinical practice, without any additional intervention.
Patients with primary or secondary liver tumors
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Endovascular treatment for patients with primary and secondary liver tumors
Also known as: Transarterial Chemoembolisation, Transarterial Radioembolization, Bland Transarterial Embolization, Hepatic Vein Embollization, Portal Vein Embolization
Progression free survival
Treatment Efficacy
Time frame: Short term (3-6 months)
Progression free survival
Time frame: From time of intervention up to 1 year (medium term)
Progression free survival
Time frame: From time of intervention up to 5 years (Long term)
Residual hepatic volume
Treatment Efficacy
Time frame: within 40 days of procedure
Overall survival
Overall survival
Time frame: From date of procedure until the date of death from any cause, whichever came first, assessed up to 5 years
Started May 2021 (actual). Primary completion is estimated for Dec 2026, 67 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.